Results 11 to 20 of about 495,297 (403)
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Journal of the American Medical Association (JAMA), 2022 Importance
Cardiovascular disease (CVD) is the leading cause of mortality in the US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 people in the US have a first myocardial infarction and an estimated 610 000 experience a first ...K. Davidson, M. Barry, C. Mangione, Michael Cabana, D. Chelmow, Tumaini R. Coker, E. Davis, Katrina E. Donahue, C. Jaén, A. Krist, Martha Y. Kubik, Li Li, G. Ogedegbe, L. Pbert, J. Ruiz, J. Stevermer, Chien-Wen Tseng, J. Wong +17 moresemanticscholar +1 more sourceEffect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Journal of the American Medical Association (JAMA), 2022 Importance
There remains a lack of randomized trials investigating aspirin monotherapy for symptomatic venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA).V. Sidhu, T-l Kelly, N. Pratt, S. Graves, R. Buchbinder, S. Adie, K. Cashman, Ilana Ackerman, Durga Bastiras, R. Brighton, A. Burns, B. Chong, O. Clavisi, Maggie Cripps, Mark Dekkers, R. de Steiger, Michael C. Dixon, Andrew Ellis, E. Griffith, D. Hale, Amber Hansen, A. Harris, R. Hau, M. Horsley, Dugal James, Omar Khorshid, L. Kuo, P. Lewis, David Lieu, M. Lorimer, S. Macdessi, P. Mccombe, C. McDougall, J. Mulford, J. Naylor, R. Page, J. Radovanović, M. Solomon, R. Sorial, P. Summersell, P. Tran, W. Walter, S. Webb, Christopher J Wilson, D. Wysocki, I. Harris +45 moresemanticscholar +1 more sourceAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
medRxiv, 2021 Background: Aspirin has been proposed as a treatment for COVID-19 on the basis of its antithrombotic properties. Methods: In this randomised, controlled, open-label trial, several possible treatments were compared with usual care in patients hospitalised P. Horby, G. Pessoa-Amorim, N. Staplin, J. Emberson, M. Campbell, E. Spata, L. Peto, N. Brunskill, Simon Tiberi, Victor Chew, Thomas M. Brown, H. Tahir, B. Ebert, D. Chadwick, T. Whitehouse, R. Sarkar, Clive Graham, J. Baillie, B. Basnyat, M. Buch, L. Chappell, J. Day, S. Faust, R. Hamers, T. Jaki, E. Juszczak, K. Jeffery, W. Lim, A. Montgomery, A. Mumford, K. Rowan, G. Thwaites, M. Mafham, R. Haynes, M. Landray +34 moresemanticscholar +1 more sourceAspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
Journal of the American Medical Association (JAMA), 2021 Importance
Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality.K. Davidson, M. Barry, C. Mangione, M. Cabana, A. Caughey, E. Davis, Katrina E. Donahue, Chyke A Doubeni, Martha Y. Kubik, Li Li, G. Ogedegbe, L. Pbert, Michael Silverstein, M. Simon, J. Stevermer, Chien-Wen Tseng, J. Wong +16 moresemanticscholar +1 more sourceComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
New England Journal of Medicine, 2021 BACKGROUND
The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.W. S. Jones, H. Mulder, Lisa M. Wruck, M. Pencina, S. Kripalani, D. Muñoz, David Crenshaw, M. Effron, R. Re, K. Gupta, R. Anderson, C. Pepine, E. Handberg, Brittney Manning, Sandeep K Jain, S. Girotra, D. Riley, D. DeWalt, J. Whittle, Ythan Goldberg, V. Roger, R. Hess, C. Benziger, Peter M. Farrehi, Li Zhou, D. Ford, K. Haynes, Jeffrey J. Vanwormer, K. Knowlton, J. Kraschnewski, Tamar S. Polonsky, D. Fintel, F. Ahmad, J. McClay, James R. Campbell, Douglas S. Bell, G. Fonarow, S. Bradley, Anuradha Paranjape, M. Roe, Holly R. Robertson, L. Curtis, Amber Sharlow, L. Berdan, B. Hammill, Debra F. Harris, Laura G. Qualls, Guillaume Marquis-Gravel, M. Modrow, G. Marcus, T. Carton, E. Nauman, L. Waitman, Abel Kho, E. Shenkman, K. McTigue, R. Kaushal, F. Masoudi, E. Antman, Desiree R Davidson, K. Edgley, J. G. Merritt, Linda Brown, Doris N Zemon, Thomas E McCormick, Jacqueline D. Alikhaani, K. Gregoire, R. Rothman, R. Harrington, Adrian F. Hernandez +69 moresemanticscholar +1 more sourceNasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease [PDF]
, 2013 Background
Aspirin-exacerbated respiratory disease is under-diagnosed and therefore effective and inexpensive therapy with aspirin desensitization is rarely performed.Darby, Y, Gane, S, Larco, J, Miller, B, Mirakian, R, Sannah, AA, Scadding, G +6 morecore +1 more sourceAspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study
BMC Gastroenterology, 2020 Background Aspirin has been found to lower the occurrence rates of some cancers through the inhibition of the cyclooxygenase enzyme. For example, there is a well-known association between aspirin use and the occurrence of hepatocellular carcinoma (HCC ...Yen-Hsiang Liao, Ren-Jun Hsu, Tzu-Hwei Wang, Chen-Ta Wu, Sheng-Yao Huang, Chung-Y. Hsu, Yuan-Chih Su, Wen-Lin Hsu, Dai-Wei Liu +8 moredoaj +1 more sourceIs clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]
, 2014 ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...Chang, Ku-Chou, Lee, Hsuei-Chen, Lee, Jiann-Der, Lee, Meng, Lee, Tsong-Hai, Ovbiagele, Bruce, Rao, Neal M, Saver, Jeffrey L, Wang, Hui-Hsuan, Wu, Chih-Ying, Wu, Yi-Ling +10 morecore +1 more sourceAnti-cancer effects and mechanism of actions of aspirin analogues in the treatment of glioma cancer [PDF]
, 2012 INTRODUCTION: In the past 25 years only modest advancements in glioma treatment have been made, with patient prognosis and median survival time following diagnosis only increasing from 3 to 7 months.A. A. Hill, A. Altinkaya, A. Baborie, A. Bahl, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Brodbelt, A. Chalmers, A. Dubocq, A. Eason, A. Elmahdi, A. Frary, A. Frary, A. Gerhard, A. Gullan, A. Hajitou, A. J. Frary, A. Jackson, A. James, A. James, A. Joannides, A. Kia, A. Niranjan, A. O'Brien, A. Shaw, A. Shenoy, A. Shivane, A. Shoakazemi, A. Singh, A. Singleton, A. Sofat, A. Sottoriva, A. Williamson, A. Young, A. Young, B. Hacking, B. Harding, B. Haylock, B. Haylock, B. Haylock, B. Herron, C. Chatelain, C. Crosby, C. Davis, C. Hanemann, C. L. Nigro, C. Lawrence, C. O. Hanemann, C. Romanowski, C. Schmidberger, C. Walker, C. Walker, C. Walker, C. Watts, C. Watts, C. Watts, D. A. Jellinek, D. Bowyer, D. Cavers, D. Conkey, D. Coope, D. Crooks, D. Crooks, D. Crooks, D. du Plessis, D. Elder, D. G. O'Donovan, D. Husband, D. J. Coope, D. Kondziolka, D. Parkinson, D. Sheer, D. Thompson, D. W. Ellison, E. A. Chiocca, E. Clarke, E. Ercolano, E. Goessl, E. Hatzimichael, E. Healy, E. McGrath, E. Murray, F. Harris, F. McKevitt, F. Roncaroli, F. Roncaroli, F. Rowther, F. Rowther, F. Rowther, F. Turkheimer, G. Cruickshank, G. Hall, G. Hall, G. J. Pilkington, G. J. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Pilkington, G. Thompson, G. Wall, G. Zilidis, H. Coley, H. Dogra, H. Kano, H. Kardooni, H. Wong, I. C. Morley, I. Corbett, I. Craven, I. Nicholl, I. Noorani, I. Qaddoumi, I. R. Whittle, I. Spiteri, J. Alder, J. Baily, J. Bambrough, J. Bambrough, J. Bomalaski, J. Darling, J. Darling, J. Darling, J. Darling, J. Darling, J. Dunn, J. Dunn, J. Harney, J. Holliday, J. Ironside, J. Larsen, J. Leggate, J. Logan, J. M. Przystal, J. N. Jeyapalan, J. Simpson, J. Singh, J. Tavare, K. Ashkan, K. Ashkan, K. Ashton, K. Ashton, K. Ashton, K. Chen, K. Das, K. E. Hatherell, K. Herholz, K. Hopkins, K. Hopkins, K. Janczar, K. Karabatsou, K. Karabatsou, K. Karakoula, K. Karakoula, K. Kroese, K. M. Kurian, K. M. Kurian, K. M. Kurian, K. M. Prise, K. McCarthy, K. O'Neil, K. Phipps, K. Prise, L. Brazil, L. Donovan, L. Evans, L. Lattanzio, L. Lunsford, L. Mohsen, L. Rada, L. Shaw, L. Spinelli, L. Steele, L. Taggart, L. Wallace, L. Zhou, M. A. Mumin, M. Altinkaya, M. Anand, M. Anand, M. Arora, M. Barczyk, M. Boissinot, M. Bradley, M. C. Schmid, M. Diaz, M. Donnelly, M. Frame, M. Jenkinson, M. Jenkinson, M. Jenkinson, M. Keeling, M. Mackinnon, M. McLean, M. Morris, M. R. Morris, M. Williams, N. A. Pullen, N. A. Pullen, N. Burnet, N. Cohen, N. D. Mazarakis, N. Hoggard, N. Marko, N. Nianiaris, N. Potter, N. R. Leslie, N. Rathi, N. Rathi, N. Syed, O. Sansom, O. Thomas, P. Brennan, P. Collins, P. Grundy, P. J. Mintz, P. Metherall, P. Singh, P. Singh, P. Szlosarek, P. Tibarewal, P. Welsby, Q. An, R. Beaney, R. Bhangoo, R. Blake, R. Brock, R. G. Tatevossian, R. Grundy, R. Hamilton, R. Hayward, R. Hinz, R. Jackson, R. Jena, R. Lea, R. McConnell, R. Muirhead, R. P. Pangeni, R. Rahman, S. Al-Rashid, S. Ammoun, S. Ammoun, S. Bell, S. Bell, S. Birks, S. Birks, S. Birks, S. Birks, S. Green, S. Hafizi, S. Hafizi, S. Higgins, S. J. Price, S. J. Price, S. J. Price, S. Jefferies, S. Kokkinos, S. Lawler, S. Leow-Dyke, S. Leow-Dyke, S. Leow-Dyke, S. Mashal, S. McQuaid, S. Price, S. Price, S. Price, S. Price, S. Saini, S. Scott, S. Shepherd, S. Smith, S. T. Al Rashid, S. Tavare, S. Wilkins, S. Williams, S. Williams, T. Crook, T. Dawson, T. Dawson, T. Dawson, T. Flannery, T. Flannery, T. Gaissmaier, T. J. Warr, T. Jacques, T. Jaunky, T. Lawson, T. Smith, T. Van Meter, T. Warr, T. Warr, T. Warr, T. Warr, T. Warr, V. Beckett, V. Berry, V. Bosak, V. Brunton, V. Hurwitz, V. Iyer, V. Iyer, V. Lupson, V. Petinou, W. Harkness, W. Stewart, W. Stewart, Y. Majani, Y. Zhang, Z. Hanzely, Z. Hanzely, Z. Maherally, Z. Su +312 morecore +1 more source
